Now who would of thought, $HTBX
Roth Capital Analysts Give Heat Biologics Inc. (HTBX) a $2.00 Price Target
December 6th, 2016 - By Jessica Moore - 0 comments
Heat Biologics Inc. logoRoth Capital set a $2.00 price objective on Heat Biologics Inc. (NASDAQ:HTBX) in a research report released on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
HTBX has been the topic of several other research reports. Zacks Investment Research downgraded shares of Heat Biologics from a buy rating to a hold rating in a research note on Tuesday, October 18th. Noble Financial restated a buy rating and issued a $8.00 price objective on shares of Heat Biologics in a research note on Wednesday, August 17th. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $6.19.
Shares of Heat Biologics (NASDAQ:HTBX) opened at 1.11 on Thursday. The company has a 50 day moving average of $1.52 and a 200-day moving average of $1.17. Heat Biologics has a 12-month low of $0.40 and a 12-month high of $4.71. The firm’s market cap is $26.51 million.
Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.07. Equities research analysts forecast that Heat Biologics will post ($0.63) EPS for the current fiscal year.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
